<img alt="" src="https://secure.perk0mean.com/184504.png" style="display:none;">

 

How RTSM Has Evolved with Rising Clinical Trial Complexity

About the Episode

Get ready to disrupt the old ways of thinking and discover the newest trial trends! In today’s episode, Kathleen and Libbi have a conversation with Simon West-Bulford, director of test automation at 4G Clinical, about the evolution of randomization technology and how modern RTSM systems have developed to address the high degree of complexity found in today's clinical trials.

Simon brings over 33 years of experience in the pharmaceutical industry to the table, with 20 of those years being focused on interactive response technologies. He takes into account the whole span of his career as he first defines IRT and RTSM for listeners, sharing how early forms of IRT (Interactive Response Technology) gave rise to RTSM (Randomization and Trial Supply Management). The evolution in technology coincided with evolution in how trials were conducted, and Simon explains how he has seen both sides of this evolution progress over time. He focused much of his own efforts on the supply aspect of trials, working on the innovative SPARC project while at GSK, engaging with both Ramos and Trident, and watching different supply organizations push each other to innovate.

While Simon saw clinical trials themselves grow in complexity over time, he notes that the experience of working in the shifting clinical trials industry was not just a matter of trials becoming more complicated. In some instances, advances in technology allowed more complex studies to be made; in other words, technology advanced first, and those creating clinical trials had newfound freedom to explore the use cases for that technology. As he looks to the future, Simon expects to see still more evolution in both technology and clinical trials. The current demand for flexibility and speed in the clinical trial space will, he believes, lead to further automation. Other topics of interest in the space involve personalized medication, the push toward decentralization, and how to use nanotechnology. With so many new ideas and tools in the medical field and the tech space, the sky’s the limit for the clinical trial field and the tech developers helping it to advance!

See Who's Talking

LIBBI RICKENBACHER

VP, Marketing and Partnerships

Libbi Rickenbacher, Vice President of Marketing and Partnerships at 4G Clinical, brings extensive industry experience across clinical research, commercial strategy, brand leadership, and partnership development. She leads global marketing and strategic partnership initiatives with a focus on positioning 4G Clinical for growth, strengthening market presence, and building meaningful industry collaboration. At 4G Clinical, Libbi is responsible for shaping brand strategy, advancing thought leadership, driving go-to-market execution, and developing partnerships that support innovation across the clinical trial ecosystem. Libbi holds a BA in psychology and neuroscience and a PhD in neuroscience.

Subscribe to our podcast